Published in J Pediatr Hematol Oncol on August 01, 2003
Dysregulated arginine metabolism, hemolysis-associated pulmonary hypertension, and mortality in sickle cell disease. JAMA (2005) 6.14
Vasculopathy in sickle cell disease: Biology, pathophysiology, genetics, translational medicine, and new research directions. Am J Hematol (2009) 2.05
Levels of soluble endothelium-derived adhesion molecules in patients with sickle cell disease are associated with pulmonary hypertension, organ dysfunction, and mortality. Br J Haematol (2005) 1.69
Hydroxyurea nitrosylates and activates soluble guanylyl cyclase in human erythroid cells. Blood (2007) 1.27
Relationship of erythropoietin, fetal hemoglobin, and hydroxyurea treatment to tricuspid regurgitation velocity in children with sickle cell disease. Blood (2009) 1.16
Sickle cell disease and nitric oxide: a paradigm shift? Int J Biochem Cell Biol (2006) 1.13
Hematologic, biochemical, and cardiopulmonary effects of L-arginine supplementation or phosphodiesterase 5 inhibition in patients with sickle cell disease who are on hydroxyurea therapy. Eur J Haematol (2008) 1.04
The vascular effects of different arginase inhibitors in rat isolated aorta and mesenteric arteries. Br J Pharmacol (2009) 0.98
Sickle cell disease: new opportunities and challenges in Africa. ScientificWorldJournal (2013) 0.97
Redox-dependent impairment of vascular function in sickle cell disease. Free Radic Biol Med (2007) 0.93
Correlation of low levels of nitrite and high levels of fetal hemoglobin in patients with sickle cell disease at baseline. Rev Bras Hematol Hemoter (2012) 0.93
Pharmacotherapy in sickle cell disease--state of the art and future prospects. Br J Haematol (2009) 0.92
A randomized, placebo-controlled trial of arginine therapy for the treatment of children with sickle cell disease hospitalized with vaso-occlusive pain episodes. Haematologica (2013) 0.84
The capacity of red blood cells to reduce nitrite determines nitric oxide generation under hypoxic conditions. PLoS One (2014) 0.79
Cough and wheeze events are temporally associated with increased pain in individuals with sickle cell disease without asthma. Br J Haematol (2015) 0.79
Haptoglobin gene polymorphisms and interleukin-6 and -8 levels in patients with sickle cell anemia. Rev Bras Hematol Hemoter (2015) 0.79
The role of the arginine metabolome in pain: implications for sickle cell disease. J Pain Res (2016) 0.76
Asthma management in sickle cell disease. Biomed Res Int (2013) 0.75
Saudi Guidelines on the Diagnosis and Treatment of Pulmonary Hypertension: Pulmonary hypertension associated with hemolytic anemia. Ann Thorac Med (2014) 0.75
Dysregulated arginine metabolism, hemolysis-associated pulmonary hypertension, and mortality in sickle cell disease. JAMA (2005) 6.14
Heterogeneity of hemoglobin H disease in childhood. N Engl J Med (2011) 2.97
Arginine therapy: a new treatment for pulmonary hypertension in sickle cell disease? Am J Respir Crit Care Med (2003) 2.93
VEGF modulates erythropoiesis through regulation of adult hepatic erythropoietin synthesis. Nat Med (2006) 2.67
Mammalian long-chain acyl-CoA synthetases. Exp Biol Med (Maywood) (2008) 2.28
Revised nomenclature for the mammalian long-chain acyl-CoA synthetase gene family. J Lipid Res (2004) 2.08
Longitudinal changes in brain magnetic resonance imaging findings in children with sickle cell disease. Blood (2002) 2.02
Decreased arginine bioavailability and increased serum arginase activity in asthma. Am J Respir Crit Care Med (2004) 2.01
Induction of arginase I transcription by IL-4 requires a composite DNA response element for STAT6 and C/EBPbeta. Gene (2005) 2.00
Tropomodulin 1-null mice have a mild spherocytic elliptocytosis with appearance of tropomodulin 3 in red blood cells and disruption of the membrane skeleton. Blood (2010) 1.99
Translational control of inducible nitric oxide synthase expression by arginine can explain the arginine paradox. Proc Natl Acad Sci U S A (2003) 1.92
Elevated levels of the 64-kDa cleavage stimulatory factor (CstF-64) in lipopolysaccharide-stimulated macrophages influence gene expression and induce alternative poly(A) site selection. J Biol Chem (2005) 1.74
Microenvironments in tuberculous granulomas are delineated by distinct populations of macrophage subsets and expression of nitric oxide synthase and arginase isoforms. J Immunol (2013) 1.62
Quality of life in patients with thalassemia intermedia compared to thalassemia major. Ann N Y Acad Sci (2005) 1.59
Increased prevalence of iron-overload associated endocrinopathy in thalassaemia versus sickle-cell disease. Br J Haematol (2006) 1.57
Human term placenta as a source of hematopoietic cells. Exp Biol Med (Maywood) (2009) 1.51
Physical therapy alone compared with core decompression and physical therapy for femoral head osteonecrosis in sickle cell disease. Results of a multicenter study at a mean of three years after treatment. J Bone Joint Surg Am (2006) 1.44
Managing sickle cell disease. BMJ (2003) 1.43
Adenosine promotes alternative macrophage activation via A2A and A2B receptors. FASEB J (2011) 1.38
Effect of eculizumab on haemolysis-associated nitric oxide depletion, dyspnoea, and measures of pulmonary hypertension in patients with paroxysmal nocturnal haemoglobinuria. Br J Haematol (2010) 1.35
Activities of arginase I and II are limiting for endothelial cell proliferation. Am J Physiol Regul Integr Comp Physiol (2002) 1.35
Hemolysis-associated pulmonary hypertension in thalassemia. Ann N Y Acad Sci (2005) 1.35
Mammalian acyl-CoA:lysophosphatidylcholine acyltransferase enzymes. Proc Natl Acad Sci U S A (2007) 1.33
Pulmonary hypertension in thalassemia: association with platelet activation and hypercoagulable state. Am J Hematol (2006) 1.31
Nitrite-generated NO circumvents dysregulated arginine/NOS signaling to protect against intimal hyperplasia in Sprague-Dawley rats. J Clin Invest (2011) 1.30
Amplified expression profiling of platelet transcriptome reveals changes in arginine metabolic pathways in patients with sickle cell disease. Circulation (2007) 1.29
Pulmonary hypertension and NO in sickle cell. Blood (2010) 1.28
Regulation of macrophage arginase expression and tumor growth by the Ron receptor tyrosine kinase. J Immunol (2011) 1.26
Arginase-2 mediates diabetic renal injury. Diabetes (2011) 1.25
Erythrocyte glutamine depletion, altered redox environment, and pulmonary hypertension in sickle cell disease. Blood (2007) 1.17
Imaging of the diffusion of single band 3 molecules on normal and mutant erythrocytes. Blood (2009) 1.12
Macrophage arginase regulation by CCAAT/enhancer-binding protein beta. Shock (2005) 1.11
Activity of the acyl-CoA synthetase ACSL6 isoforms: role of the fatty acid Gate-domains. BMC Biochem (2010) 1.08
Clinical differences between children and adults with pulmonary hypertension and sickle cell disease. Br J Haematol (2007) 1.08
Effect of hydroxyurea on growth in children with sickle cell anemia: results of the HUG-KIDS Study. J Pediatr (2002) 1.07
Multiple erythroid isoforms of human long-chain acyl-CoA synthetases are produced by switch of the fatty acid gate domains. BMC Mol Biol (2006) 1.06
Hydrolysis of phosphatidylserine-exposing red blood cells by secretory phospholipase A2 generates lysophosphatidic acid and results in vascular dysfunction. J Biol Chem (2005) 1.06
Inhibition of phosphodiesterase 4 amplifies cytokine-dependent induction of arginase in macrophages. Am J Physiol Lung Cell Mol Physiol (2005) 1.05
Transfusion prevents acute chest syndrome predicted by elevated secretory phospholipase A2. Br J Haematol (2006) 1.04
Pulmonary hypertension in thalassemia. Ann N Y Acad Sci (2010) 1.01
Sildenafil therapy in thalassemia patients with Doppler-defined risk of pulmonary hypertension. Haematologica (2013) 0.99
Chelation use and iron burden in North American and British thalassemia patients: a report from the Thalassemia Longitudinal Cohort. Blood (2012) 0.98
In vivo reduction of erythrocyte oxidant stress in a murine model of beta-thalassemia. Haematologica (2004) 0.98
Bone mineral density in children with sickle cell anemia. Pediatr Blood Cancer (2006) 0.98
The effects of disruption of genes for peroxiredoxin-2, glutathione peroxidase-1, and catalase on erythrocyte oxidative metabolism. Free Radic Biol Med (2009) 0.96
Determination of mammalian arginase activity. Methods Enzymol (2008) 0.96
LXRα regulates macrophage arginase 1 through PU.1 and interferon regulatory factor 8. Circ Res (2011) 0.96
Thrombin induces endothelial arginase through AP-1 activation. Am J Physiol Cell Physiol (2009) 0.95
Identification of an erythroid ATP-dependent aminophospholipid transporter. Br J Haematol (2006) 0.95
Retinoic acid promotes the development of Arg1-expressing dendritic cells for the regulation of T-cell differentiation. Eur J Immunol (2013) 0.95
Dose-escalation study of ICA-17043 in patients with sickle cell disease. Pharmacotherapy (2006) 0.94
The central role of arginine catabolism in T-cell dysfunction and increased susceptibility to infection after physical injury. Ann Surg (2014) 0.94
Disparity in the management of iron overload between patients with sickle cell disease and thalassemia who received transfusions. Transfusion (2008) 0.94
Characterization of low bone mass in young patients with thalassemia by DXA, pQCT and markers of bone turnover. Bone (2011) 0.93
Tapered oral dexamethasone for the acute chest syndrome of sickle cell disease. Br J Haematol (2011) 0.92
Fetal haemoglobin augmentation in E/beta(0) thalassaemia: clinical and haematological outcome. Br J Haematol (2005) 0.92
Multipotent stromal stem cells from human placenta demonstrate high therapeutic potential. Stem Cells Transl Med (2012) 0.92
A 29-kDa protein associated with p67phox expresses both peroxiredoxin and phospholipase A2 activity and enhances superoxide anion production by a cell-free system of NADPH oxidase activity. J Biol Chem (2002) 0.91
Large-scale arrays of picolitre chambers for single-cell analysis of large cell populations. Lab Chip (2010) 0.91
Reactive oxygen species and phosphatidylserine externalization in murine sickle red cells. Br J Haematol (2004) 0.90
Arginase activities and global arginine bioavailability in wild-type and ApoE-deficient mice: responses to high fat and high cholesterol diets. PLoS One (2010) 0.90
Iron homeostasis during transfusional iron overload in beta-thalassemia and sickle cell disease: changes in iron regulatory protein, hepcidin, and ferritin expression. Pediatr Hematol Oncol (2007) 0.90
A simple assay for frequency of chromosome breaks and loss (micronuclei) by flow cytometry of human reticulocytes. FASEB J (2004) 0.89
Treatment of heart failure in adults with thalassemia major: response in patients randomised to deferoxamine with or without deferiprone. J Cardiovasc Magn Reson (2013) 0.89
Protein kinase C activation induces phosphatidylserine exposure on red blood cells. Biochemistry (2002) 0.89
Selective increase of autoimmune epitope expression on aged erythrocytes in mice: implications in anti-erythrocyte autoimmune responses. J Autoimmun (2002) 0.88
A pilot study of subcutaneous decitabine in β-thalassemia intermedia. Blood (2011) 0.88
Altered red cell turnover in diabetic mice. J Lab Clin Med (2002) 0.88
Cloning of human agmatinase. An alternate path for polyamine synthesis induced in liver by hepatitis B virus. Am J Physiol Gastrointest Liver Physiol (2002) 0.88
Nitric oxide-mediated suppression of detrusor overactivity by arginase inhibitor in rats with chronic spinal cord injury. Urology (2008) 0.87
Shaping the murine macrophage phenotype: IL-4 and cyclic AMP synergistically activate the arginase I promoter. J Immunol (2013) 0.87
Arginase inhibition mediates renal tissue protection in diabetic nephropathy by a nitric oxide synthase 3-dependent mechanism. Kidney Int (2013) 0.87
Biochemical responses of healthy subjects during dietary supplementation with L-arginine. J Nutr Biochem (2004) 0.87
The 'intestinal-renal' arginine biosynthetic axis in the aging rat. Mech Ageing Dev (2002) 0.86
ATP8A1 activity and phosphatidylserine transbilayer movement. J Receptor Ligand Channel Res (2008) 0.85
Deferiprone and hepatic fibrosis. Blood (2003) 0.85